COMPASS Pathways is in a technical breakout with an attractively priced setup and large modeled upside to its analyst target, but sub-floor business quality, a mixed earnings track record, and a purely speculative small-cap classification keep conviction and position sizing at essentially zero.
Thesis pillars
- Quality Below Investability Floor→Stable
- Golden Cross Breakout With Soft Momentum→Stable
- Attractive Valuation Vs Analyst Target→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 24, 2026
COMPASS Pathways Plc - American (CMPS) Stock Analysis
Inst Constrain edge
Healthcare · Medical Care Facilities
Sell if holding. Engine safety override at $12.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality.
COMPASS Pathways is a clinical-stage biotechnology company developing COMP360, a proprietary pharmaceutical-grade psilocybin treatment, as a novel therapy for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Both Phase 3 pivotal trials in TRD met... Read more
Sell if holding. Engine safety override at $12.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 4d<=7d. Suitability: aggressive.
About COMPASS Pathways Plc - American
About COMPASS Pathways Plc - American
COMPASS Pathways completed enrollment in both Phase 3 pivotal trials of COMP360 psilocybin treatment for treatment-resistant depression (TRD) in 2025, and both trials, COMP005 and COMP006, met their primary endpoints by February 2026 with statistically significant reductions in depression severity (p<0.001). The company reported a $287.9 million net loss for 2025 against an $822.6 million accumulated deficit, with $149.6 million in cash as of December 31, 2025 expected to fund operations into 2028.
COMPASS has generated no product revenue since its 2020 IPO and has funded development entirely through equity offerings, warrants and debt; it retains worldwide development and commercialization rights to COMP360 and plans a U.S. launch, targeting launch readiness by the end of 2026 if COMP360 is approved. TRD affects an estimated 4 million treated adults in the U.S., a subset of the roughly 23 million U.S. adults with major depressive disorder, and current options are limited to esketamine and an olanzapine-fluoxetine combination; COMPASS is following its TRD data with an FDA meeting request on a rolling NDA submission. Beyond TRD, the company advanced COMP360 into a Phase 2b/3 trial in PTSD after positive Phase 2a results, with FDA acceptance of the IND in January 2026, and has previously explored anorexia nervosa as a further indication. Commercialization will also require DEA and state-level scheduling decisions given psilocybin's controlled-substance status.
Show full overview
COMPASS Pathways' near-term value is concentrated entirely in one molecule, COMP360, tested so far only in TRD, PTSD and anorexia nervosa: the 10-K states the company is focusing all of its efforts on progressing the Phase 3 TRD program and the Phase 2b/3 PTSD trial, with no other product candidates in active development to diversify against a setback. Because COMPASS has never generated product revenue and depends on additional financing to reach commercialization, a negative FDA decision, an unfavorable DEA scheduling determination for a psilocybin-based product, or a failure to replicate Phase 3 results in the ongoing long-term follow-up periods would remove the company's only near-term path to revenue.
See also: Healthcare · Medical Care Facilities
From COMPASS Pathways Plc - American's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — COMPASS Pathways Plc - American
Latest news
- NEWS COMPASS Pathways to Highlight Scientific Research and TRD Disease State Education at 2026 NEI Fall Congress — fiscal.ai Oct 29, 2026 neutral
- NEWS Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026 — fiscal.ai Oct 27, 2026 neutral
- NEWS Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript — benzinga Oct 8, 2026 neutral
- NEWS Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression — benzinga Sep 9, 2026 positive
- NEWS Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resista — benzinga Sep 9, 2026 positive
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineCOMP360 psilocybin treatment (sole clinical program)10-K Item 1: 'We are currently focusing our efforts on progressing our Phase 3 clinical program in TRD and our Phase 2b/3 clinical trial in PTSD.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.42. Score 5.4/10, moderate confidence.
Analyst target: $21.38 (+74.1% upside). Prior stop was $11.42. Stop-loss: $11.42.
Concentration risk — Pipeline: COMP360 psilocybin treatment (sole clinical program); Quality below floor (1.6 < 4.0).
COMPASS Pathways Plc - American trades at a P/E of N/A (forward -8.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts cover CMPS with a consensus score of 4.3/5. Average price target: $24.
What does COMPASS Pathways Plc - American do?COMPASS Pathways is a clinical-stage biotechnology company developing COMP360, a proprietary pharmaceutical-grade...
COMPASS Pathways is a clinical-stage biotechnology company developing COMP360, a proprietary pharmaceutical-grade psilocybin treatment, as a novel therapy for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Both Phase 3 pivotal trials in TRD met their primary endpoints by early 2026, and the company plans to submit an NDA to the FDA in the fourth quarter of 2026; it has not generated any product revenue to date and reported a $287.9 million net loss in 2025.